---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-019186"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2023-05-26T23:59:59+00:00"
generated_at: "2026-06-14T13:12:05.041281+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharmaceuticals Regains Nasdaq Compliance After Late Filing, Provides Pipeline Update

## Summary
- Received delisting notice from Nasdaq on May 24 for failure to timely file Form 10-Q, but filed on May 25 and regained compliance.
- Closed private placement of $4.3M secured convertible note and warrants for $4.0M investment.
- Expects final submission to FDA for Phase II trial of Ropidoxuridine in glioblastoma by end of Q2 2023.
- Awarded U.S. Patent No. 11,654,157 for cancer therapies combining halogenated thymidines and thymidine phosphorylase inhibitors with radiation.
- Appointed Dr. Bette Jacobs as independent director to Board.

## SEC filing metadata
- accession: 0001493152-23-019186
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2023-05-26T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315223019186/0001493152-23-019186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315223019186/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-019186
- JSON: https://secwatch.observer/filing/0001493152-23-019186.json
- Plain text: https://secwatch.observer/filing/0001493152-23-019186.txt

## Key facts
- Listing & Compliance Notices
  Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 12B-25).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: late filing
  - Rules: 12B-25
  source text: May 24, 2023, the Company received notice from the Nasdaq Stock Market, LLC (“Nasdaq”) that we have fallen out of compliance with the Nasdaq Listing Rules for continued listing as a result of being unable to file our Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the “Form 10-Q”) within the five day extension provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. Our Form 10-Q had not been timely filed as a result of certain accounting complexities that arose in relation to our convertible note held by Alto Opportunity Master Fund, SPC – Segregated M
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315223019186/0001493152-23-019186-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.